Medicine
Neuraceq 135 mCi/mL injection
Neuraceq 135 mCi/mL injection is a prescription medicine containing Florbetaben f-18 for intravenous use, marketed by Lantheus Biosciences Ltd., a Lantheus, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store NEURACEQ in the original container with radiation shielding at room…
Key facts
- Active ingredient (INN)
- Florbetaben f-18
- Brand
- Neuraceq
- Strength
- 135 mCi/mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- Lantheus Biosciences Ltd., a Lantheus
- Manufacturer
- Lantheus Biosciences Ltd., a Lantheus
- Origin register
- US FDA, United States
- Storage
- Store NEURACEQ in the original container with radiation shielding at room temperature 25°C (77°F), excursions permitted to 2°C to 42°C (36°F to 108°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V09AX06 Florbetaben
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 March 2014
- Identifiers
- DailyMed set ID b0915068-cfd4-4d72-b9f8-7e31fe83cd1eNDC 54828-001Application NDA204677
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, multi-dose in 1 container / 50 mL in 1 vial, multi-dose | 54828-001-50 | Lantheus Biosciences Ltd., a Lantheus | 13 June 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 19 March 2014 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Florbetaben f-18 is a radioactive diagnostic agent. It is available as injection for intravenous use. MedsAcross supplies Florbetaben f-18 for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Florbetaben f-18For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Neuraceq prescribing information (Lantheus Biosciences Ltd., a Lantheus) · U.S. National Library of Medicine, DailyMed
Need Neuraceq 135 mCi/mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.